Search research articles
Contact Us
Filters
Showing results (1301-1310 of 1,860) with videos related to
Page
of 186
Sort By:
Circulation
|
February 10, 2022
Second Heart Field-Derived Cells Contribute to Angiotensin II-Mediated Ascending Aortopathies
Hisashi Sawada, Yuriko Katsumata, Hideyuki Higashi, et al.
JCI Insight
|
December 6, 2022
LRP1 protects against excessive superior mesenteric artery remodeling by modulating angiotensin II-mediated signaling
Jackie M Zhang, Dianaly T Au, Hisashi Sawada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2018
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
Zhongxing Liao, J Jack Lee, Ritsuko Komaki, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
April 20, 2023
[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]
S Lu, X M Yu, Y P Hu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
B Pistilli, K Jhaveri, S-A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, E-H Tan, K O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 25, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y-L Wu, C Zhou, C-K Liam, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 3, 2025
Endothelium- and Fibroblast-Derived C-Type Natriuretic Peptide Prevents the Development and Progression of Aortic Aneurysms
Aisah A Aubdool, Amie J Moyes, Cristina Pérez-Ternero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
J C-H Yang, L V Sequist, C Zhou, et al.
Page
of 186
Search research articles
Search
Showing results (1301-1310 of 1,860) with videos related to
Sort By:
Page
of 186
Circulation
|
February 10, 2022
Second Heart Field-Derived Cells Contribute to Angiotensin II-Mediated Ascending Aortopathies
Hisashi Sawada, Yuriko Katsumata, Hideyuki Higashi, et al.
JCI Insight
|
December 6, 2022
LRP1 protects against excessive superior mesenteric artery remodeling by modulating angiotensin II-mediated signaling
Jackie M Zhang, Dianaly T Au, Hisashi Sawada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2018
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
Zhongxing Liao, J Jack Lee, Ritsuko Komaki, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
April 20, 2023
[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]
S Lu, X M Yu, Y P Hu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
B Pistilli, K Jhaveri, S-A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, E-H Tan, K O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 25, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y-L Wu, C Zhou, C-K Liam, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 3, 2025
Endothelium- and Fibroblast-Derived C-Type Natriuretic Peptide Prevents the Development and Progression of Aortic Aneurysms
Aisah A Aubdool, Amie J Moyes, Cristina Pérez-Ternero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
J C-H Yang, L V Sequist, C Zhou, et al.
Page
of 186